Clinical Observation of Recombinant Human Growth Hormone Injection Assisted IVF-ET in the Treatment of PCOS

Inclusion Criteria: * Age between 25 and 35 years old, married female and infertile. * BMI≥25kg/m2. * Diagnosed as PCOS. * No obvious chronic organic diseases, such as liver, kidney, heart, lung, thyroid, adrenal disease. * Subjects do not take part in other clinical trial study within 3 months. * The subjects sign the informed consent form. Exclusion Criteria: * BMI\<25kg/m2. * Hyperprolactinemia and congenital adrenal cortical hyperplasia. * Diabetes, thyroid function hyperthyroidism, thyroid dysfunction, cushing's syndrome. * Pelvic and peritoneal tumor and tumor secreting hyperandrogenism. * Severe acute and chronic liver and kidney disease, such as liver cirrhosis, acute and chronic renal failure, hepatitis B virus activity. * Liver and kidney dysfunction, AST/ALT is 2.5 times higher than the normal limit, the serum of creatinine is 2 times higher than the normal level. * Diseases affecting outcome of IVF pregnancy, eg, hydrosalpinx, hysteromyoma\>4 cm, adenomyosis, endometriosis, endometrial cyst of ovary, unilateral ovary, tuberculosis of reproductive system. * Allergic to E. coli. expression product and its excipients. * Being involved in other drug clinical researchers. * The researchers consider who is not suitable for the group.